Results From the First Randomised Study in Multicentric Castleman's Disease, a Rare Lymphoproliferative Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Siltuximab, an Anti -Interleukin-6 Monoclonal Antibody
mag（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要